IN8bio to present data on potential of INB-400 to target ovarian cancer

IN8bio will present preclinical data showcasing the potential of INB-400 to target ovarian cancer at the American Society of Cell & Gene Therapy, ASGCT, Annual Meeting, in Los Angeles from May 16-20. High-grade serous ovarian cancer, HGSOC, is the most common and devasting form of ovarian cancer, comprising approximately 70-80% of deaths. While poly ADP-ribose polymerase inhibitors, PARPi, have improved patient outcomes, recurrence remains a significant obstacle and unmet medical need. INB-400 is an O6-methylguanine-DNA methyltransferase genetically engineered, chemotherapy resistant gamma-delta T cell product that can recognize and kill cancer cells. INB-400 has shown promising results in preclinical studies, demonstrating a powerful synergistic combination of chemotherapy and gamma-delta T cell therapy to eliminate residual cancer cells. The new data to be presented at ASGCT builds on that success, demonstrating the ability of INB-400 to target and kill multiple ovarian cancer cell lines. "We believe the technology targeting the DNA damage response pathway underlying our INB-400 program has broad applicability across many solid tumor cancers," said Lawrence Lamb, Ph.D., co-founder and Chief Scientific Officer of IN8bio. "These data demonstrate the potential of gamma-delta T cells to target and kill solid tumor cells outside the brain. We are encouraged by these findings and will continue exploring the potential of INB-400 across a broad range of solid tumors where new treatment options are urgently needed."